HAS A 3-FOLD DECREASED DOSE OF BACILLUS CALMETTE-GUERIN THE SAME EFFICACY AGAINST RECURRENCES AND PROGRESSION OF T1G3 AND TIS BLADDER TUMORS THAN THE STANDARD DOSE? RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL
Abstract
Purpose:
We determined if a third of the dose of intravesical bacillus Calmette-Guerin (BCG) has the same efficacy than a standard dose for decreasing the risk of recurrence and progression after transurethral resection in patients with superficial high risk (stages T1G3 and carcinoma in situ) bladder cancer. Also, we evaluated toxic side effects.
Material and Methods:
A total of 155 patients with a mean age ± SD of 67 ± 10.1 years with superficial bladder cancer, including stages T1G3 in 90, a Tis primary tumor in 23 and associated Tis disease in 42, were enrolled and randomly assigned to be treated after transurethral resection of all visible lesions with intravesical BCG, Connaught strain (weekly × 6 and fortnightly × 6 thereafter) with the standard dose of 81 mg or with the decreased dose of 27 mg.
Results:
Median followup was 61 months (range 3 to 102). Disease recurred in 32 patients (39%) treated with the standard dose and in 33 (45%) treated with the decreased dose. Median time to recurrence was not attained in the standard dose arm and it was 63 months in the decreased dose arm. Kaplan-Meier estimates for time to recurrence did not reveal differences between the 2 doses (p = 0.405). Tumor progressed in 20 patients (24.7%) with the standard dose and in 19 (26%) with the decreased dose. Four patients (6.1%) with Tis had local extension into the prostatic urethra and ducts, including 3 (8.3%) treated with the standard dose and 1 (3.4%) treated with the decreased dose. Median time to progression was not attained in either arm. Kaplan-Meier estimates for time to progression did not differ significantly (p = 0.7997). Deferred cystectomy for progression was performed in 7 patients (8.4%) treated with the standard dose and in 7 (9.5%) of those treated with the decreased dose. Subgroup analysis by patient age, tumor status, number, size and T stage (T1G3 vs Tis) did not differ significantly. The groups did not differ in disease specific mortality, which was 12.2% in the standard dose arm and 16.4% in the decreased dose arm. Mean disease specific survival ± SE was 86.96 ± 4.14 and 83.73 ± 4.73 months, respectively.
Conclusions:
Our results suggest that a 3-fold decreased dose of intravesical BCG is as effective as the standard dose against progression in patients with high risk stages T1G3 and Tis superficial bladder carcinoma but with significantly less toxicity.
References
- 1 : Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int2002; 89: 671. Google Scholar
- 2 : Low dose vs standard dose BCG therapy of superficial bladder cancer: final results of a phase 3 randomized trial. Eur Urol, suppl.1999; 35. abstract 152. Google Scholar
- 3 : Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. J Urol1992; 147: 1256. Link, Google Scholar
- 4 : The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder. J Urol2001; 165: 401. Link, Google Scholar
- 5 : Low-dose bacille Calmette-Guerin (BCG) therapy in superficial high-risk bladder cancer: a phase II study with the BCG strain Connaught Canada. Br J Urol1995; 75: 185. Google Scholar
- 6 : Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success. Eur Urol1998; 34: 67. Google Scholar
- 7 : Intravesical bacille Calmette-Guerin in stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology1999; 54: 258. Google Scholar
- 8 : Profilaxis de los tumores superficiales de vejiga T1 con 27 mg de BCG semanal durante 6 semanas. Arch Esp Urol1999; 52: 760. Google Scholar
- 9 : Low-dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J Urol2000; 163: 68. Link, Google Scholar
- 10 : Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations. J Urol2000; 163: 63. Link, Google Scholar
- 11 : Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J Urol1992; 148: 797. Link, Google Scholar
- 12 : Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder. J Urol1996; 155: 1907. Link, Google Scholar
- 13 : Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol1997; 80: 762. Google Scholar
- 14 : Long term follow-up of 98 patients with T1G3 transitional cell carcinoma of the bladder treated with BCG. Br J Urol1997; 80. abstract 140. Google Scholar
- 15 : Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology2002; 59: 227. Google Scholar
- 16 : Intravesical Bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours. Eur Urol2002; 41: 635. Google Scholar
- 17 : A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol2003; 169: 96. Link, Google Scholar
- 18 : Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol2002; 168: 1964. Link, Google Scholar
- 19 : Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol2000; 163: 1124. Link, Google Scholar
- 20 : Bladder Cancer Clinical Guidelines Panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and Tis). J Urol1999; 162: 1697. Link, Google Scholar
From the La Luz Clinic (JAM-P), La Paz Hospital (LM-P, SA, RM) and Hospital de San Carlos (JRM), Madrid, Instituto Valenciano de Oncología (ES), Valencia, Valdecilla Hospital (RHR), Santander, Complejo Hospitalario de Oviedo (JMFG) and Hospital Juan Canalejo (MGM), La Coruña, Hospital La Mancha (AGC), Alcázar de San Juan, Hospital Civil de Basurto (NF) and Hospital de Cruces (CP), Bilbao, Hospital Negrín (SI), Las Palmas, Hospital de la Princesa (MR) and Hospital de Galdácano (AA), Vizcaya and Hospital SAS de Jerez (JEC), Jerez, Spain
